These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6734036)

  • 41. [An experimental and clinical pharmacological study of the influence of triamterene on the diuretic and saluretic properties of furosemide xantinol].
    Celdrán E; Bekett PR; Roberts DJ
    Arzneimittelforschung; 1976; 26(11):2073-6. PubMed ID: 14648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Age dependence of the pharmacokinetics of triamterene].
    Stopp M; Bräunlich H
    Acta Biol Med Ger; 1973; 30(1):121-32. PubMed ID: 4707945
    [No Abstract]   [Full Text] [Related]  

  • 44. [Pathogenesis and therapy of ascites in liver cirrhosis].
    Dölle W
    Internist (Berl); 1966 Jan; 7(1):48-54. PubMed ID: 4861685
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacodynamics of acidic triamterene derivatives and their esters and amides.
    Priewer H; Kraft H; Mutschler E
    Arzneimittelforschung; 1985; 35(10):1544-7. PubMed ID: 4074412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption.
    Muirhead M; Bochner F; Somogyi A
    J Pharmacol Exp Ther; 1988 Feb; 244(2):734-9. PubMed ID: 3346844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [ON MODIFICATIONS OF PLASMA AND URINARY ELECTROLYTES IN ASCITOGENIC HEPATIC CIRRHOSIS IN TREATMENT WITH TRIAMTERENE ALONE AND ASSOCIATED WITH HYDROCHLOROTHIAZIDE AND WITH SPIRONOLACTONE].
    MELLONI GF; BARATTA C; MARANGONI R; MERLO L; ANTOGNETTI R
    Minerva Med; 1964 Sep; 55():2722-37. PubMed ID: 14199461
    [No Abstract]   [Full Text] [Related]  

  • 49. Triamterene increases lithium excretion in healthy subjects: evidence for lithium transport in the cortical collecting tubule.
    Wetzels JF; van Bergeijk JD; Hoitsma AJ; Huysmans FT; Koene RA
    Nephrol Dial Transplant; 1989; 4(11):939-42. PubMed ID: 2516883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil.
    Shaheen O; Patel J; Avant GR; Hamilton M; Wood AJ
    Clin Pharmacol Ther; 1986 Dec; 40(6):650-5. PubMed ID: 3780126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Influence of triamterene, aldactone and amilorid on the electrolyte excretion following oral potassium loading test in rats].
    Formanek K; Hohenegger M
    Wien Klin Wochenschr; 1970 Mar; 82(13):240-1. PubMed ID: 5419661
    [No Abstract]   [Full Text] [Related]  

  • 52. The effects of a combination of piretanide and triamterene in healthy subjects.
    Daneshmend TK; Homeida M; Roberts CJ; Dombey S
    Br J Clin Pharmacol; 1981 Jan; 11(1):106-8. PubMed ID: 7213503
    [No Abstract]   [Full Text] [Related]  

  • 53. Femoxetine clearance in patients with liver cirrhosis.
    Hansen BA; Mengel H; Keiding S; Lund J
    Acta Pharmacol Toxicol (Copenh); 1984 Nov; 55(5):386-90. PubMed ID: 6528808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic fate and solubility of triamterene--not an explanation for triamterene nephrolithiasis.
    Sörgel F; Ettinger B; Benet LZ
    J Pharm Sci; 1986 Feb; 75(2):129-32. PubMed ID: 3958920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Propranolol in the treatment of cirrhotic ascites.
    Rector WG; Reynolds TB
    Arch Intern Med; 1984 Sep; 144(9):1761-3. PubMed ID: 6476994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [CONTRIBUTION TO THE STUDY OF THE ACTION OF TRIAMTERENE IN THE TREATMENT OF ALCOHOLIC CIRRHOSIS WITH ASCITES. (APROPOS OF 24 CASES)].
    FRAISSE H; ETAIX JP
    J Med Lyon; 1964 Jan; 45():167-72. PubMed ID: 14113139
    [No Abstract]   [Full Text] [Related]  

  • 57. The natriuretic and diuretic characteristics of triamterene in the dog.
    Wiebelhaus VD; Brennan FT; Sosnowski G; Maass AR; Weinstock J; Bender AD
    Arch Int Pharmacodyn Ther; 1967 Oct; 169(2):429-51. PubMed ID: 6064571
    [No Abstract]   [Full Text] [Related]  

  • 58. [Diuretic effect of triamterene in the experimental animal].
    Sala G
    Minerva Med; 1963 Oct; 54(81 Suppl):2983-5. PubMed ID: 5877326
    [No Abstract]   [Full Text] [Related]  

  • 59. [On the diuretic and saluretic activity of p-hydroxytriamterene and methoxytriamterene (author's transl)].
    Vollmer G; Mutschler E; Völger KD
    Arzneimittelforschung; 1981; 31(3):529-30. PubMed ID: 7194678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A student exercise in clinical pharmacology: Renal effects of diuretics.
    Gilmore JP; O'Brien WM; Brand ED; Peach MJ; Westfall TC
    Curr Ther Res Clin Exp; 1970 Nov; 12(11):759-69. PubMed ID: 4993129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.